Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Molecular Partners ( (MOLN) ) has provided an announcement.
Molecular Partners and Orano Med have expanded their strategic partnership to develop up to ten programs of targeted alpha radio-therapies (TAT) for cancer, leveraging their combined expertise in DARPin therapeutics and lead-212-based radiopharmaceuticals. This collaboration is expected to enhance their leadership in the field by accelerating development timelines and expanding their radiotherapy pipeline, though there are no immediate financial impacts anticipated for Molecular Partners for the fiscal year 2025.
More about Molecular Partners
Molecular Partners AG is a clinical-stage biotech company specializing in the design and development of DARPin therapeutics, aimed at addressing medical challenges that other drug modalities cannot easily tackle. With a primary focus on oncology, the company utilizes its proprietary DARPin platform to provide innovative solutions for patients and collaborates with leading pharmaceutical firms. Founded in 2004, Molecular Partners operates from Zurich, Switzerland, and Concord, Massachusetts, USA.
YTD Price Performance: 2.32%
Average Trading Volume: 25,147
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $200.2M
Find detailed analytics on MOLN stock on TipRanks’ Stock Analysis page.
